Participants with diseases that affect healing (e.g. diabetes)
Immunocompromised participants
Participants with aphthous herpetiform ulceration or major aphthous ulceration
Participants using medication to treat oral ulcerations (systemic or local)
Participants who used analgesics or anti-inflammatory drugs in the 6 hours prior to the beginning of the study
Participants who used systemic antibiotics in the 2 weeks prior to the beginning of the study
Participants using medications that can confuse pain assessment (psychotropics, antidepressants and sedative-hypnotics), except when on a stable dose for at least 30 days prior to the screening visit, and the dose cannot be changed during the clinical trial
Participants with current smoking habits
Participants who are pregnant, breastfeeding or planning to get pregnant or female participants with the potential to become pregnant who are not using a reliable method of contraception
Known hypersensitivity to the formula components used during the clinical trial
Participants with current or medical history of cancer in the last 5 years
Participants who participated in other research protocol in the last 12 months, unless the investigator judges that there may be a direct benefit to it
Sites
EMS - Pharma Farmacêutica
Rod. Jorn. Francisco Aguirre Proença - Parque Odimar, Hortolândia - SP, Brazil